D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy).

[1]  Alireza Sepehri Shamloo,et al.  Diagnostic Value of D-Dimer in Acute Myocardial Infarction Among Patients With Suspected Acute Coronary Syndrome , 2018, Cardiology research.

[2]  S. Goldhaber,et al.  Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial , 2017, Thrombosis and Haemostasis.

[3]  H. Naruse,et al.  Prognostic Value of Combination of Plasma D-Dimer Concentration and Estimated Glomerular Filtration Rate in Predicting Long-Term Mortality of Patients With Stable Coronary Artery Disease. , 2017, Circulation journal : official journal of the Japanese Circulation Society.

[4]  M. Gul,et al.  Predictive values of D-dimer assay, GRACE scores and TIMI scores for adverse outcome in patients with non-ST-segment elevation myocardial infarction , 2017, Therapeutics and clinical risk management.

[5]  G. Palareti,et al.  Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and Drug Administration guideline. Results of a multicenter management study , 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[6]  Murali Krishna Gurram,et al.  Effectiveness of D-Dimer as a Screening Test for Venous Thromboembolism: An Update , 2014, North American journal of medical sciences.

[7]  G. Lip,et al.  d-Dimer elevation and adverse outcomes , 2014, Journal of Thrombosis and Thrombolysis.

[8]  S. Goldhaber,et al.  The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. , 2014, American heart journal.

[9]  F. Breuckmann,et al.  Impact of d-Dimers on the Differential Diagnosis of Acute Chest Pain: Current Aspects Besides the Widely Known , 2014, Clinical Medicine Insights. Cardiology.

[10]  I. Pabinger,et al.  Biomarkers for prediction of venous thromboembolism in cancer. , 2013, Blood.

[11]  A. T. ten Cate‐Hoek,et al.  D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease , 2013, Thrombosis and Haemostasis.

[12]  G. Stone,et al.  D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy , 2013, Journal of Thrombosis and Thrombolysis.

[13]  O. Chassany,et al.  A multicentric prospective study in usual care: D-dimer and cardiovascular events in patients with atrial fibrillation. , 2012, Thrombosis research.

[14]  A. Gori,et al.  Thrombosis and acute coronary syndrome. , 2012, Thrombosis research.

[15]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[16]  A. Shimony,et al.  Meta-analysis of usefulness of d-dimer to diagnose acute aortic dissection. , 2011, The American journal of cardiology.

[17]  S. Hayes,et al.  Fibrin D-Dimer Concentration, Deep Vein Thrombosis Symptom Duration, and Venous Thrombus Volume , 2011, Angiology.

[18]  Xiaoying Li,et al.  Measurement of D-dimer as aid in risk evaluation of VTE in elderly patients hospitalized for acute illness: a prospective, multicenter study in China. , 2011, Clinical and investigative medicine. Medecine clinique et experimentale.

[19]  L. Wallentin,et al.  Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome , 2010, Thrombosis and Haemostasis.

[20]  Georg Heinze,et al.  Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism: The Vienna Prediction Model , 2010, Circulation.

[21]  J. Mega,et al.  Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial , 2009, The Lancet.

[22]  F. Klok,et al.  Elevated d‐dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta‐analysis , 2009, Journal of thrombosis and haemostasis : JTH.

[23]  P. Moerloose,et al.  D‐Dimer for venous thromboembolism diagnosis: 20 years later , 2008, Journal of thrombosis and haemostasis : JTH.

[24]  Filippo Crea,et al.  La inflamación en los síndromes coronarios agudos: mecanismos e implicaciones clínicas , 2004 .

[25]  A. Turpie,et al.  Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. , 2004, Archives of pathology & laboratory medicine.

[26]  F. Bernardi,et al.  Predictive Value of D‐Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia , 2003, Circulation.

[27]  Jeffrey S. Ginsberg,et al.  Decrease in sensitivity of D-dimer for acute venous thromboembolism after starting anticoagulant therapy , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[28]  A. Siegbahn,et al.  Coagulation activity and clinical outcome in unstable coronary artery disease. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[29]  G. Lowe,et al.  Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. , 1995, The American journal of cardiology.

[30]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[31]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (1). , 1992, The New England journal of medicine.